Nonalcoholic fatty liver disease estimated to cost $103 billion annuallyOctober 4, 2016Liver DiseaseObesity
Investigational HCV drug combo yields high SVR12 rates in compensated cirrhosisOctober 1, 2016Liver Disease
Analysis yields ‘strong evidence’ for benefit of physical activity in NAFLDOctober 1, 2016Liver Disease
Ceftazidime-avibactam stands up to CRE, but resistance a problemSeptember 29, 2016IBD & Intestinal Disorders
Medicare’s revaluation of gastrointestinal endoscopic procedures: Implications for academic and community-based practicesSeptember 26, 2016Practice Management
